Worse PFS when radiation is withheld in early-stage Hodgkin lymphomaSeptember 19, 2019Lymphoma & Plasma Cell Disorders
Staging PET/CT better defines extent of mantle cell lymphomaSeptember 19, 2019Lymphoma & Plasma Cell Disorders
Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMDSeptember 19, 2019Lymphoma & Plasma Cell Disorders
Study confirms prognostic impact of MYC partner gene in DLBCLSeptember 17, 2019DLBCLLymphoma & Plasma Cell Disorders
VRD pretransplant induction deepens responses in myelomaSeptember 17, 2019Lymphoma & Plasma Cell Disorders
Rituximab, bendamustine look better than chemo alone in MCLSeptember 7, 2019Lymphoma & Plasma Cell Disorders
Progressive myeloma after induction? Go straight to transplantSeptember 6, 2019Lymphoma & Plasma Cell Disorders
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCLAugust 27, 2019Lymphoma & Plasma Cell Disorders
Combo produces responses in triple-class refractory myelomaAugust 21, 2019Lymphoma & Plasma Cell Disorders
Obinutuzumab-lenalidomide combo shows promise in relapsed/refractory FLAugust 21, 2019Follicular LymphomaLymphoma & Plasma Cell Disorders
Brentuximab vedotin plus nivolumab shows positive outcomes in PMBLAugust 20, 2019Lymphoma & Plasma Cell Disorders
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCLAugust 12, 2019Lymphoma & Plasma Cell Disorders
Cardiovascular complications most common with carfilzomib in relapsed myelomaAugust 9, 2019Lymphoma & Plasma Cell DisordersPatient & Survivor Care
